Systemic Estrogens: Selecting the Right Agent Within the Class

What the Systemic Estrogen Class Is and How It Works

Systemic estrogens are exogenous estrogen preparations that achieve circulating serum concentrations sufficient to act on tissues beyond the urogenital tract, distinguishing them from local vaginal preparations. The class prototype is oral 17-beta estradiol. All agents bind estrogen receptors (ER-alpha and ER-beta) and regulate transcription of hundreds of downstream genes governing thermoregulation, bone remodeling, lipid metabolism, and vascular tone.

The North American Menopause Society (NAMS) 2022 Position Statement states directly: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture." [1]

ER-Alpha vs. ER-Beta Selectivity

ER-alpha predominates in the uterus, liver, breast, and bone. ER-beta is more abundant in the ovary, colon, and central nervous system. Oral and transdermal estradiol both activate both receptor subtypes. No commercially available systemic estrogen in the United States is selectively ER-beta agonist only.

Serum Estradiol Targets

A practical serum estradiol target for vasomotor symptom control is 40 to 100 pg/mL. Below 30 pg/mL, most patients experience incomplete relief. Above 150 pg/mL, endometrial proliferation risk increases substantially and does not confer additional symptom benefit. Clinicians should check trough serum estradiol 4 to 6 weeks after initiating a patch or gel, particularly when titrating dose.

Oral Estrogens: First-Pass Metabolism and Its Consequences

Oral administration sends estrogen directly through the portal circulation before entering systemic distribution. This hepatic first-pass converts up to 90 percent of ingested 17-beta estradiol to estrone, produces a 4-to-6:1 estrone-to-estradiol ratio, and substantially elevates hepatic protein synthesis.

Hepatic Effects of Oral Estrogens

Oral estrogens increase sex-hormone-binding globulin (SHBG), C-reactive protein, triglycerides, and coagulation factors VII and X. The ESTHER study (N=881) found that oral estrogen users had a 4-fold higher risk of VTE compared with non-users, while transdermal estradiol users showed no significant increase in risk (OR 0.9, 95% CI 0.45 to 1.8). [2]

Clinicians should avoid oral estrogens in patients with hypertriglyceridemia (fasting triglycerides above 400 mg/dL), personal history of VTE, or inherited thrombophilia.

Conjugated Equine Estrogens (CEE)

CEE (Premarin) is derived from pregnant mare urine and contains at least 10 distinct estrogen compounds, including equilin and equilenin sulfates. These equine estrogens have longer half-lives than estradiol and maintain biologic activity even after the patient stops therapy. The Women's Health Initiative (WHI) used CEE 0.625 mg/day plus medroxyprogesterone acetate (MPA) 2.5 mg/day as its combination arm (N=16,608), and estrogen-alone CEE 0.625 mg/day in the hysterectomy arm (N=10,739). [3]

The WHI reported a hazard ratio of 1.26 (95% CI 1.00 to 1.59) for invasive breast cancer in the CEE plus MPA arm, but an HR of 0.77 (95% CI 0.62 to 0.95) for breast cancer in the CEE-alone arm at 7.2 years. [3] These data suggest the breast-cancer signal in the original WHI was partly attributable to MPA rather than CEE.

Oral 17-Beta Estradiol

Oral micronized estradiol (Estrace, generics) provides the same molecule produced by the human ovary. Available doses are 0.5 mg, 1 mg, and 2 mg. Oral estradiol 1 mg/day raises serum estradiol to approximately 40 to 80 pg/mL, though inter-individual variation is wide because intestinal CYP3A4 and CYP2C9 affect pre-systemic metabolism.

Estradiol valerate (generic, not branded in the US at this time) is an ester that hydrolyzes to 17-beta estradiol after absorption; it is effectively bioequivalent to micronized estradiol at equal milligram doses.

Transdermal Estradiol: The Preferred Route in High-Thrombosis-Risk Patients

Transdermal delivery bypasses hepatic first-pass metabolism entirely. The result is a physiologic estradiol-to-estrone ratio (roughly 1:1), minimal SHBG induction, no clinically meaningful increase in coagulation factors, and stable 24-hour serum levels without the estrone peaks seen orally.

Patches

Reservoir-type and matrix patches deliver 0.025, 0.0375, 0.05, 0.075, or 0.1 mg of estradiol per 24 hours. Most are changed twice weekly (Vivelle-Dot, Climara Pro) or once weekly (Climara). Adhesion failure rates are higher in humid climates, and rotating sites across the lower abdomen and buttocks reduces skin reactions.

The Nurses' Health Study analysis of 59,000 postmenopausal women found that transdermal estrogen users did not have the elevated stroke risk observed with oral estrogen use (RR 1.45, 95% CI 1.10 to 1.92 for oral users vs. RR 0.81, 95% CI 0.62 to 1.05 for transdermal). [4] That divergence has direct clinical meaning for patients with controlled hypertension or prior ischemic events.

Gels and Sprays

Estradiol gel (EstroGel 0.06%, Divigel 0.1%) is applied to the arm or thigh once daily. Standard starting doses are 0.75 g of EstroGel (delivering 0.75 mg estradiol) or 0.25 g of Divigel. The spray formulation (Evamist, 1.53 mg/actuation) is applied to the inner forearm.

Transfer to partners or children via skin contact is a documented FDA safety concern with gels and sprays. Patients must allow the application site to dry completely and cover it before contact. [5] This risk does not apply to patches.

Transdermal Estradiol Dosing Reference

A practical dose-equivalence framework often cited in clinical practice:

• Patch 0.05 mg/day: approximate serum estradiol 40 to 60 pg/mL
• Patch 0.1 mg/day: approximate serum estradiol 80 to 120 pg/mL
• EstroGel 1.5 g/day: approximate serum estradiol 50 to 80 pg/mL
• Oral estradiol 1 mg/day: approximate serum estradiol 40 to 80 pg/mL (high variability)

These are population medians. Individual pharmacokinetics vary enough that serum monitoring is preferred over dose assumptions alone.

Vaginal Ring (Systemic Dose): Femring

The vaginal ring Femring delivers estradiol acetate at 0.05 mg or 0.1 mg per 24 hours for 90 days before replacement. Unlike Estring (which delivers only 7.5 mcg/day locally), Femring achieves systemic serum estradiol concentrations comparable to a low-to-mid dose transdermal patch. It is the only vaginal ring indicated for systemic vasomotor symptom relief.

Femring avoids the hepatic first-pass effect like other non-oral routes. Patients with uterine prolapse or discomfort with vaginal insertion are not good candidates. Acceptance rates are highest among patients who prefer a quarterly dosing schedule.

Compounded Bioidentical Hormones: What the Evidence Says

Compounded estrogens (typically estradiol, estriol, or "bi-est" or "tri-est" mixtures) are marketed as individualized alternatives. The FDA does not review compounded products for safety or efficacy, and no large randomized controlled trial has evaluated any compounded estrogen formulation for clinical outcomes. [5]

The NAMS 2022 statement explicitly notes: "The Endocrine Society and NAMS do not recommend custom-compounded hormones as a first-line therapy for menopausal symptoms, as there is a lack of reliable evidence for safety and efficacy, and the content and purity of these products cannot be assured." [1]

Estriol is the weakest of the three endogenous estrogens and is not FDA-approved as a systemic therapeutic in the United States. The argument that it is "safer" due to lower potency is not supported by clinical trial data against approved alternatives.

Selecting the Agent: A Clinical Decision Framework

Step 1. Establish Route Based on VTE and Cardiovascular Risk

For patients with no personal history of VTE and BMI <30, oral estradiol is a reasonable choice if the patient prefers a tablet. For patients with BMI above 30, prior superficial thrombophlebitis, active tobacco use, controlled hypertension, or a first-degree relative with VTE, transdermal estradiol is the safer route. [2,4]

Step 2. Match Formulation to Adherence Profile

Twice-weekly patch users in one pharmacy database had 12-month adherence rates of approximately 68 percent versus 54 percent for daily oral tablets. Quarterly Femring users had the highest 12-month continuation in the same analysis. The best formulation is the one the patient will actually use.

Step 3. Decide on CEE vs. 17-Beta Estradiol

For patients who have never used hormone therapy, 17-beta estradiol is the clinically preferred starting molecule in most contemporary guidelines because it is the endogenous human estrogen, its pharmacokinetics are better characterized, and the serum assay directly measures therapeutic levels. CEE remains an appropriate choice for patients who have used it successfully before or who have a clinical reason to avoid estradiol-specific metabolism.

Step 4. Set the Starting Dose

NAMS and the Endocrine Society both recommend starting at the lowest effective dose and titrating upward based on symptom response after 8 to 12 weeks. [1,6] Starting doses:

• Oral estradiol: 0.5 to 1 mg daily
• Transdermal patch: 0.025 to 0.05 mg/day
• EstroGel: 0.75 g/day (one pump)
• CEE oral: 0.3 to 0.625 mg daily

Step 5. Add Progestogen in Any Patient With an Intact Uterus

Unopposed systemic estrogen produces endometrial hyperplasia in approximately 15 to 32 percent of patients within one year and carries a 2- to 12-fold elevated endometrial carcinoma risk with long-term use. [7] The choice of progestogen (micronized progesterone, MPA, norethindrone acetate, or an IUD with levonorgestrel) affects the breast and lipid profile and is a separate clinical decision.

Key Drug Interactions and Monitoring Parameters

Drug Interactions

CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) accelerate estradiol metabolism and may reduce serum levels below therapeutic targets. CYP3A4 inhibitors (ketoconazole, grapefruit juice in high quantities) may raise estradiol levels. These interactions are more clinically significant with oral estrogens because first-pass CYP3A4 activity is already the dominant metabolic pathway.

Thyroid replacement doses may need upward adjustment when initiating oral estrogen because the increase in thyroxine-binding globulin reduces free T4. Transdermal estrogen does not meaningfully raise TBG.

Monitoring

• Serum estradiol: check at 4 to 6 weeks after initiation or dose change; target 40 to 100 pg/mL for symptom control
• Blood pressure: recheck at 3 months after starting any estrogen
• Fasting lipids and triglycerides: at baseline and 6 months for oral estrogens (triglycerides may rise; LDL typically falls)
• Endometrial surveillance: not routine unless abnormal uterine bleeding occurs; symptom-triggered biopsy or transvaginal ultrasound

Special Populations

Surgical Menopause Before Age 45

Women who undergo bilateral oophorectomy before natural menopause lose estrogen abruptly. The absolute cardiovascular and bone risk of untreated surgical menopause before age 45 is substantially higher than the risk of hormone therapy in this population. [8] Full replacement doses are often appropriate: patch 0.05 to 0.1 mg/day or oral estradiol 1 to 2 mg/day, continuing until at least the median age of natural menopause (51 years).

The Nurses' Health Study found that women who underwent oophorectomy before age 50 and did not use estrogen had a 28 percent higher all-cause mortality compared to women with intact ovaries (RR 1.28, 95% CI 1.15 to 1.43). [8]

Patients With Migraine With Aura

Oral estrogens' cyclical peaks and troughs can trigger menstrual-pattern migraines. A low-dose transdermal patch provides stable serum estradiol with fewer hormonal fluctuations. The American Headache Society supports transdermal estrogen as the preferred route in migraine with aura, though combined estrogen-progestogen therapy in this population still carries a debated ischemic stroke signal.

Patients With Hypertriglyceridemia

Oral estrogens raise triglycerides. In patients with fasting triglycerides above 400 mg/dL, transdermal estrogen is mandatory. The triglyceride elevation with oral CEE 0.625 mg has been documented at 25 to 40 percent above baseline in clinical series. Transdermal estradiol 0.05 mg/day produces no statistically significant change in triglycerides. [9]

Duration of Use and Stopping

The FDA label language recommending "the shortest duration consistent with goals" reflects WHI-era conservatism that the NAMS 2022 statement explicitly qualifies. For women who begin therapy before age 60 or within 10 years of menopause onset, the "timing hypothesis" suggests a favorable or neutral cardiovascular risk profile. [1] The Kronos Early Estrogen Prevention Study (KEEPS, N=727) found no difference in carotid intima-media thickness progression between oral CEE, transdermal estradiol, and placebo after 4 years when therapy began within 3 years of menopause. [10]

Abrupt discontinuation after long-term use can trigger rebound vasomotor symptoms. A tapered approach, such as stepping down one dose level every 8 weeks, reduces symptom recurrence during withdrawal.

Safety, Contraindications, and Absolute Stops

Absolute contraindications per FDA labeling and NAMS consensus include:

• Known or suspected pregnancy
• Unexplained abnormal genital bleeding
• Known, suspected, or personal history of breast cancer
• Known or suspected estrogen-sensitive malignancy
• Active DVT, pulmonary embolism, or recent arterial thromboembolic event (within 12 months)
• Active liver disease or hepatic impairment with transaminases above 3 times the upper limit of normal
• Known protein C, protein S, or antithrombin deficiency (oral estrogen contraindicated; transdermal risk is lower but individualize)

Relative contraindications include uncontrolled hypertension, gallbladder disease (oral estrogens increase bile saturation by roughly 50 percent), and active migraine with aura.